Brainstorm cell therapeutics announces full year 2022 financial results and provides a corporate update

Biologics license application for nurown® for the treatment of als to be discussed in an upcoming fda advisory committee meeting conference call and webcast at 8:00 a.m. eastern time today new york , march 30, 2023 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended december 31, 2022 and provided a corporate update.
BCLI Ratings Summary
BCLI Quant Ranking